
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.67054
Urology
Acute Phase Peyronie’s Disease: Where Do We Stand?
Muacevic Alexander
Adler John R
Douroumis Konstantinos 1
Kotrotsios Konstantinos 1
Katsikatsos Panagiotis 1
Moulavasilis Napoleon 1
Fragkiadis Evangelos 1
Mitropoulos Dionysios 1
Adamakis Ioannis 1
1 Department of Urology, National and Kapodistrian University of Athens, Athens, GRC
Konstantinos Douroumis kostasdour@hotmail.com
17 8 2024
8 2024
16 8 e6705417 8 2024
Copyright © 2024, Douroumis et al.
2024
Douroumis et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/281585-acute-phase-peyronies-disease-where-do-we-stand
Peyronie’s disease (PD) is a common benign condition characterized by superficial fibrosis and scar formation at the tunica albuginea of the penis, eventually leading to penile curvature. It is believed that penile micro-traumas during intercourse and subsequent activation of inflammatory processes constitute the pathogenetic basis of the disease. Routinely, PD is divided into acute and chronic phases, with pain during erection or flaccid state being the hallmark of the former. Surgical intervention should be avoided during the acute phase, as the risk of recurrence or progression of penile deformity during this stage might affect the optimal outcomes of the procedure. During this stage, many conservative treatment options have been suggested, including oral, topical, and intralesional therapies, extracorporeal shock wave therapy (ESWT), and penile traction therapy (PTT). Currently, the optimal treatment consists of a combined treatment strategy with phosphodiesterase type 5 inhibitors (PDE5Is), ESWT for pain management, PTT, and intralesional therapies. Large, well-designed randomized controlled trials (RCTs) are necessary to further elucidate the most efficient treatment option for acute phase PD. 

male sexual health
andrology
penile curvature
acute phase
peyronie disease
==== Body
pmcIntroduction and background

Peyronie’s disease (PD) is a benign condition that was first described by Francois Gigot de la Peyronie more than 250 years ago [1]. Despite being known for over two centuries, PD still besets a great proportion of the male population, as manifested in a large survey of 8,000 men, where the prevalence of PD was calculated as high as 389:100,000 [2]. More recent data estimate that the condition is present in around 0.3% to 13.1% of men globally, with the prevalence increasing in specific sub-populations, such as in men operated on for radical prostatectomy. [3] Additionally, another recent survey demonstrated that the prevalence of definitive and probable cases of Peyronie’s disease in the USA is 0.7% and 11%, respectively, indicating that it is an underdiagnosed condition [4].

Peyronie’s disease is a wound-healing disorder characterized by superficial fibrosis of the penis, appearing as an inelastic scar at tunica albuginea (TA), palpable during the flaccid state [5]. The most common areas of the penis, where the plaque develops, are, in descending order, the base, the mid-shaft area, and the distal penis [6]. The main symptom of PD is penile deformity comprised of curvature during erection, accompanied by loss of flaccid penile length, tunical indentations, or hourglass deformity with erection, and buckling or penile instability on minimal axial loading, despite maximum erection [7, 8]. Except for physical symptoms, PD, which is also associated with erectile dysfunction, poses a major psychological burden on both the patients and their partners [9, 10]. The aim of this review is to investigate the latest updates on the pathophysiology of Peyronie’s disease, thoroughly examine traditional and promising treatments of the acute phase of the disease, and present the limitations and future perspectives of current research in the field.

Review

Search strategy

A literature search was performed (December 8, 2023) using Medical Literature Analysis and Retrieval System Online (MEDLINE), PubMed, Cochrane Controlled Register of Trials (CENTRAL), Scopus, and Excerpta Medica database (EMBASE) databases. The following terms were used in the search text fields: Peyronie's disease AND (acute phase OR initial phase) AND (management OR oral therapy OR topical therapy OR surgery OR shock wave therapy OR traction therapy OR collagenase Clostridium histolyticum OR intralesional therapy). The search algorithm was adjusted for each database while maintaining a common overall architecture.

Published observational and interventional studies, clinical trial registries, and published conference abstracts in major urological or sexual medicine journals assessing the effect of any kind of treatment in patients with acute phase PD were included. Reviews, letters, and commentaries were excluded. In addition, we applied forward and backward citation searching by examining the reference list of all included studies and relevant reviews.

The abstracts of all articles were screened, and the full texts of all the relevant articles were examined for possible inclusion. A summary of the existing therapies for acute phase PD accompanied with their mechanism of action and probable adverse effects is provided in Table 1.

Table 1 Treatments for active phase Peyronie’s disease

COX: cyclooxygenase; TGF: transforming growth factor; CCh: collagenase Clostridium histolyticum; ESWT: extracorporeal shock wave therapy; PTT: penile traction therapy; PRP: platelet-rich plasma

Treatment	Route of administration	Mechanism of action	Side effects	
Non-steroidal anti-inflammatory drugs [11]	Oral/topical	Inhibit COX-1 and COX-2, inhibit fibroblast proliferation	Stomach pain, ulcers, gastrorrhagia	
Phosphodiesterase-5  inhibitors [12]	Oral	Inhibit tissue remodeling by decreasing oxidative stress	Headaches, dizziness	
Vitamin E [13]	Oral	Free radical scavenger	Nausea, diarrhea, fatigue	
Colchicine [14]	Oral	Induces collagenase activity, inhibits tubulin in leukocytes	Nausea, diarrhea, bone marrow suppression	
Pentoxifylline [15]	Oral/ perilesional	Reduces TGF-β induced collagen production	Tachycardia, rash, low blood pressure, dizziness	
Coenzyme Q [16]	Oral	Suppresses TGF-β1 expression	Upper abdominal pain, nausea vomiting	
Carnitine [17]	Oral	Reduces intracellular calcium concentration	Nausea, abdominal pain, mild euphoria, seizures	
Omega 3 [18]	Oral	Anti-inflammatory agent	Gastrointestinal distress, fishy odor	
Potaba [19]	Oral	Increase oxygen uptake, decrease serotonin concentration	Gastrointestinal distress, hypoglycemia, blue-colored skin	
Tamoxifen [20]	Oral	TGF release from fibroblasts, blockade of TGF-β receptors	Hives, difficulty breathing, swelling of the face	
Silymarin [21]	Oral	Anti-oxidant agent	Gastrointestinal distress	
Bilberry [22]	Oral	Anti-oxidant agent	Possible allergic reactions	
Propolis [22]	Oral	Anti-oxidant agent	Possible allergic reactions	
Ginkgo Biloba [21]	Oral	Anti-oxidant agent	Arrhythmias, stroke, tinnitus, seizures	
Superoxide dismutase [23]	Topical	Free radical scavenger	Pain at the application site	
CCh [24]	Intralesional	Halts extracellular remodeling	Damage or hematoma at the injection site, fever, chills	
Verapamil [25]	Intralesional	Stimulates degradation of extracellular matrix	Nausea, constipation, flu syndrome, hematoma at injection site	
Hyaluronic Acid [26]	Intralesional	Restores extracellular matrix homeostasis	Itching, numbness, headache, hematoma at the injection site	
Corticosteroids [27]	Intralesional	Inhibit the inflammation and the activity of phospholipase A2	Tissue atrophy, thinning of the skin	
Nicardipine [28]	Intralesional	Reduction of glycosaminoglycan synthesis and blockade of collagen production	Rash, ecchymosis, pain hematoma at the injection site	
Interferon-alpha 2b [29]	Intralesional	Decrease in fibroblast and collagen proliferation	Flu-like symptoms, hematoma in injection site	
ESWT [30]	Extra-corporeal	Mechanical stimulus promoting biological healing	Pain, red skin, numbness, hyperesthesia	
PTT [31]	NA	Tissue remodeling through mechanotransduction	Discomfort, pain, swelling, numbness	
PRP [32]	Intralesional	Extracellular matrix remodeling	Bleeding, tissue damage, local Infection, nerve injuries  	

Pathophysiology and natural history of the disease

The pathogenesis of the disease is not completely elucidated, but the most widely acceptable theory accuses micro-trauma and its subsequent inflammatory response of leading to fibrosis with reduction of elasticity and aberrant collagen deposition [33, 34]. Histologically, PD is characterized by immoderate production and accumulation of collagen and other components of the extracellular matrix (ECM), eventually leading to the formation of inelastic penile plaques [35]. It has already been well established that transforming growth factor (TGF-β1) plays a crucial role in the pathophysiology of the disease. More specifically, the overexpression of this cytokine promotes the differentiation of fibroblasts into myofibroblasts, which can evade apoptosis, leading to the accumulation of excessive ECM components, especially collagen types I, III, and IV [36].

Given that the ECM serves not only as a supporting structure for the cells but also as a coordinator for multiple signaling pathways by binding transmembrane receptors and soluble ligands, its modifications during repeated micro-traumas and consequent inflammation may play a role in PD development. This ECM reorganization induced by topical hypoxia, low pH, accumulation of reactive oxygen species, and production of multiple cytokines and growth factors leads to the release of latent TGF-β1 [37, 38]. At high levels of TGF-βa, redox imbalance occurs due to inhibition of antioxidant enzymes including glutathione peroxidase, glutathione synthetase, and catalase [39]. As a consequence, plasminogen activator inhibitor (PAI-1) expression is enhanced, and fibrinolysis is undermined [40]. Simultaneously high concentrations of TGF-β1 contribute to an imbalance between matrix metalloproteinases (MMP) and tissue inhibitors of matrix metalloproteinases (TIMP), reinforcing the fibrosis procedure [41]. Furthermore, other major activators of the TGF-β cascade are connective tissue growth factor and angiotensin II, through suppression of Smad7 and increase of the expression of thrombospondin-1, respectively [42, 43].

Besides TGF-β signaling, other cellular transduction pathways seem to be associated with excess myofibroblast proliferation, chronic inflammation, and fibrosis present in PD. These include Wnt/b-catenin, Notch, hedgehog, hippo, Rho/ROCK, PI3K/Akt/mTOR, p38 MAPK/ERK, JAK-STAT, and NF-kB signal pathways [35]. Additionally to all the interacting molecular pathways, specific morphological differences in TA, and especially a single-layered TA, can be more prone to disturbance due to mechanical forces applied to the penis during sexual intercourse [44].

Now, regarding the genetic background of the disease, the disrupted expression of TGF-β1 has been associated in a study with a point missense mutation in the TGF-β1 gene due to a specific single nucleotide polymorphism (rs1800471; G915C) [45]. Moreover, karyotyping and analysis of fibroblasts’ genetic samples derived from PD revealed both chromosomal and gene abnormalities related to the disease in loci responsible for ECM reorganization and cytokine production [46]. Characteristic examples include alterations in Wnt, Fas, and Bcl-2 expression. These gene modifications can maintain the fibrotic procedure by giving the myofibroblasts the ability to evade apoptosis [47-49]. Also, epigenetic mechanisms, with the main representative being histone deacetylase (HDAC) modification, seem to play a significant role in disease pathophysiology, making it a potential target for future therapies [50].

The natural history of PD is routinely divided into active and stable phases. The hallmarks of the active or acute phase are penile deformity, which might be combined with a soft plaque and pain in an erect and/or flaccid state. The severity of the penile curvature might increase (21%-48%), not change (36%-67%), or decrease (3%-13%). The acute stage of the disease commonly lasts for six to 18 months, with the pain improving or even alleviated in the majority of patients within 12 months of PD presentation. On the other hand, the stable phase is characterized by stability in penile curvature for at least three to six months and improvement or resolution of pain. During the chronic phase, other deformities, such as hourglass deformities and hinge effects, as well as shortening of the penis, can be present [7,51,52]. Except for the distinction of acute and stable phase using clinical criteria, a novel approach where neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte ratio (PLR) calculation can further assist the urologist [53]. The definitive treatment of PD is the surgical intervention, which, however, should be avoided during the acute phase, as the risk of recurrence or progression of penile deformity during this stage might affect the optimal outcomes of the procedure [54,55]. Thus, taking into account the psychological distress of the patients, as well as the pain characterizing the acute phase of the disease, these patients are in urgent need of treatment modalities that are equally effective and safe as the surgical procedure [56].

Treatment strategies

A flow diagram of the selection process is presented in Figure 1 [57]. We initially identified 331 papers, and after deduplication, 135 articles were considered eligible for title-abstract screening. Subsequently, 51 publications were selected for full-text screening, and, finally, 31 of them met the inclusion criteria and were included. Furthermore, the references of the included studies and references from other relevant studies from high-impact journals were hand-searched, and 30 papers that were lost from the initial literature search were included too.

Figure 1 A PRISMA flow diagram summarizing the selection process [57].

MEDLINE: Medical Literature Analysis and Retrieval System Online; Embase: Excerpta Medica database; CENTRAL: Cochrane Controlled Register of Trials; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Oral Therapies

Systemic administration of therapeutic regimens by the oral route was among the first non-surgical approaches to PD management described in the literature. For instance, almost five decades have passed since the publication of the earliest data with respect to the effect of procarbazine on PD progression [58, 59]. Since then, many oral agents have been proposed as hypothetically efficient treatment options.

Colchicine

The first use of colchicine in the treatment of PD was published in 1994. The hypothesis was that colchicine was already known to induce collagenase activity and decrease collagen synthesis, so it could be used in the treatment of PD. The results of this study were promising [14]. An early study showed that colchicine could be effective in the early stage of PD, especially in pain resolution [60]. Similar results were observed in a cohort of patients under 40 years of age [61]. A subsequent randomized double-blind study showed colchicine is no better than placebo [62]. Also, a study examining the alteration of penile curvature under colchicine showed conflicting results [63].

Potassium para-aminobenzoate (potaba)

Potassium para-aminobenzoate (Glenwood, LLC, Englewood, NJ) was first used in the treatment of PD in 1959 [19]. Promising results, concerning penile pain, plaque size, and curvature, in multiple studies before 2000 established the use of potaba in the treatment of acute phase PD [64-66]. A prospective randomized placebo-controlled study showed that potaba had a significant plaque-related effect. Specifically, mean plaque size decreased from 259 mm2 to 142 mm2 in the Potaba arm. In the placebo arm, the plaque size increased from 259 mm2 to 303 mm2 after six months, but decreased to 233 mm2 after 12 months, with the difference between the groups being significant (p = 0.042). On the contrary, potaba showed no effect in improving pre-existing curvature or decreasing penile pain [67]. In a retrospective study comparing Potaba as monotherapy with a combination therapy of tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitors (PDE5Is), potaba monotherapy improved plaque size and pain without statistical differences with the combination therapy, but had high drop-out rates, with 68.2% of patients discontinuing treatment within 12 weeks. Also, combination therapy showed better results in successful sexual intercourse and in the avoidance of the need for surgery [68].

Vitamin E

Scardino and Scott (1949) were the first to report the use of vitamin E (tocopherol) in the treatment of PD, making it the oldest oral therapy in the management of the disease [13]. It has antioxidant, anti-inflammatory, and anti-fibrotic properties, and it is believed to reduce the collagen deposits within the tunica albuginea. The first double-blinded, placebo-controlled study, published in 1983, showed no significant differences regarding improvement in plaque size or curvature [69]. These results were confirmed by later studies, analyzing vitamin E alone as well as in comparison with propionyl-L-carnitine [70, 71]. On the other hand, interesting results were extracted by studies examining the efficacy of vitamin E in combination with other non-surgical treatments, indicating that vitamin E might be used as part of a multimodal therapy [72, 22].

Tamoxifen

Treatment with tamoxifen showed potential based on an earlier uncontrolled trial, with improvements in penile pain and plaque shrinkage [20]. These results were questioned in a well-controlled study with patients only in the acute phase of the disease that demonstrated that treatment with tamoxifen did not improve pain, curvature, or plaque size [73]. However, the combination of tamoxifen with a PDE5I seemed to halt the progression of patients with acute PD compared to the control group receiving either vitamin E or no drug. More specifically, in the investigation group, more patients experienced an improvement in penile curvature (26.5% vs. 7.3%), and fewer patients displayed worsened curvature (12.7% vs. 26.8%) [74].

Phosphodiesterase type 5 inhibitors

Phosphodiesterase type 5 inhibitors were first used in the treatment for PD in 2003, as it was hypothesized that through the inhibition of TGF-β1, they promote the reduction of collagen deposition [12]. A retrospective clinical trial was conducted in 2011, with the aim of examining if the administration of PDE5is can promote the resolution of isolation septal scars without evidence of penile deformity. The results were encouraging, as the tadalafil group reported a higher International Index of Erectile Function (IIEF-5) score, and resolution of the septal scar was observed in 24 patients (69%) compared to three patients (10%) in the control group [75]. Also, in a head-to-head comparison with Vitamin E, 12 weeks of sildenafil administration showed significantly better outcomes in the IIEF-5 scores and pain reduction compared to the vitamin E group [76]. A recently published retrospective study examined the effect of daily tadalafil 5 mg administration in patients with acute phase PD and erectile dysfunction. This study showed that tadalafil administration in the acute phase reduces the curvature progression and improves erectile function and PD-related symptoms [77]. Finally, another recently published study showed that the addition of 50 mg daily sildenafil to pentoxifylline-colchicine combination therapy has significantly better results in the degree of curvature, pain, and erectile function compared to pentoxifylline-colchicine combination therapy alone [78]. These results, along with the absence of significant side effects of PDE5Is, have led to the widespread usage of PDE5Is in the management of the acute phase of PD.

Pentoxifylline

Pentoxifylline has been used in the treatment of acute phase PD in combination treatment with other antioxidants and topical diclofenac. Multimodal treatment with pentoxifylline was efficacious in the treatment of acute phase PD, as decreases in plaque volume, penile curvature, and pain were observed, along with recovery of penile rigidity, in contrast to the control group. An interesting result was that the treatment appeared to be more effective when pentoxifylline was administered both orally and by penile injection [15].

Coenzyme Q (CoQ)

Coenzyme Q exerts strong suppression on oxidative stress and has been recommended as a therapeutic option in active-phase PD. Poor evidence is available to support this hypothesis, with only one randomized controlled trial (RCT) demonstrating that daily doses of CoQ for six months resulted in greater improvement in sexual function, plaque size, and penile curvature compared to the placebo control group [16].

Acetyl-L-carnitine

Acetyl-L-carnitine, which is the precursor of acetylcholine, as an oral regimen has proven useful in degenerative diseases by increasing free radical metabolism and preventing intracellular calcium overload. A small 2001 RCT comparing the efficacy of orally delivered carnitine versus tamoxifen demonstrated that the former is superior regarding pain improvement, curvature decrease, and disease progression, markedly without causing any adverse effects [17]. 

Nonsteroidal anti-inflammatory drugs

As pain is the main symptom in acute-phase PD, nonsteroidal anti-inflammatory drugs may be offered for penile pain management. Treatment efficacy should be monitored periodically with an assessment of pain levels [11].

Regional therapies

The first promising results about the efficacy of topical regimen application in acute phase PD were derived from an uncontrolled phase 2 clinical trial including 13 patients. In this study, the regional use of recombinant human (rh) Cu-Zn superoxide dismutase (SOD) was able to reduce pain in all patients (p<0.05), without causing any local or systemic side effects [23]. These results constituted the basis for a phase 3 RCT, which verified the greater effectiveness of rhSOD in reducing pain in the intervention group against the placebo group (52.6% vs. 20%, respectively, p = 0.017). However, after 12 months of follow-up, it had no significant impact on plaque size or penile curvature [79].

Another RCT examined the efficacy of a gel containing not only SOD but also nicardipine and emu oil (H-100 gel). This combination of regimens being applied for six months in 22 patients managed to significantly improve penile curvature (40.8% reduction, p = 0.0014), stretched penile length (22.6% increase, p = 0.0002), and mean pain level (85.7% reduction, p = 0.004). Regarding the safety of the regime, a self-resolving rash in two patients and a more persistent rash in one patient were observed [80].

Collagenase Clostridium histolyticum (CCh)

Collagenase Clostridium histolyticum is the oldest intralesional therapy and also the most popular in managing acute phase PD. In a study conducted by Cocci et al. in 2020, 74 patients were enrolled with acute phase PD and a mean curvature of 41.1o ± 12ο. All patients received a single dose of intralesional CCh. The mean follow-up was six months. There were statistically significant results concerning the Visual Analog Scale (VAS) score both at rest and during intercourse and in terms of IIEF-5 score improvement [24].

In a retrospective study with 162 patients, Nguyen et al. investigated the efficacy of CCh in the active phase. In this single-center study, 36 patients (22%) were found to be in the active phase and the remaining 126 (78%) were in stable phase. The mean number of cycles for all patients was 3.2. After the treatment, there was a statistically significant improvement in curvature from a mean of 57.7o to 41.9o. There was no statistical difference between the two groups concerning the final change in curvature, the IIEF-5 score, or the stretched penile length. Moreover, there was no difference in treatment-related adverse events between the two groups (p = 0.356). This study indicated that CCh is efficient and safe both in the acute and stable phases of PD [81].

In a larger and multi-institutional analysis conducted by Nguyen et al., 918 patients were enrolled in the analysis, of which 134 (14.6%) were found to be in the active phase and the remaining 784 (85.4%) in the stable phase. Patients were standardized to an Investigation of Maximal Peyronie's Reduction Efficacy and Safety Studies (IMPRESS) protocol schedule of CCh injections with small variations among institutions. Penile modeling was initiated 24-72 hours after the second injection of each cycle. There was no difference in pre-treatment patient characteristics between the two groups. After treatment, there was no statistically significant difference between the acute and stable phases in the final change in curvature (13.5o vs. 15.6o, p = 0.09). In addition, there was no difference in the frequency of treatment-related adverse events between the acute phase and the stable phase. The authors concluded that the number of cycles is the only predictive factor of improvement of curvature and that CCh therapy is efficient and safe in the acute phase of PD [82].

In the most recent study, Hu et al. retrospectively assessed 330 patients from a single institution who received intralesional CCh for acute phase PD. There were two definitions of acute phase used: (1) acute phase duration ≤6 months and (2) acute phase duration ≤12 months with penile pain. Of 330 patients, 229 qualified for analysis because they had both pre-and post-treatment erect penile goniometry. The mean follow-up time was 10.5 ± 4.2 months. Two separate analyses were conducted for definition 1 and definition 2 of the acute and chronic phases of PD. Sixty-five patients (28%) met the criteria for definition 1 of the acute phase, 37 (16%) for definition 2, and 76 (33%) for either definition. There was no difference in percent change in penile curvature between acute and chronic phases using definition 1 (p = 0.89), definition 2 (p = 0.43), or either (p = 0.96). Additionally, no statistically significant difference was found in the frequency of complications between the groups of acute and chronic phases under either definition (p>0.05). Conclusively, intralesional CCh was effective and safe in the acute phase of PD using multiple definitions [83].

Calcium Channel Antagonists

Calcium channel antagonists, and more specifically verapamil, were introduced in PD treatment in 1994 by Levine et al., who first reported that verapamil injections can soften and reduce plaques in the penis [25]. Since then only a few studies have evaluated the effectiveness of intralesional verapamil injections (IVI) in patients with active phase PD, leading to not adequately convincing results. The majority of patients treated with IVI monotherapy experienced a stabilization of the curvature but exhibited an increase in stretched penile length and an improvement in penetration ability [84,85]. However, both the small sample and the short follow-up period do not permit the extraction of reliable conclusions. In contrast with verapamil, which is a non-dihydropyridine (DHP), nicardipine is a DHP and is reportedly more efficient in glycosaminoglycan biosynthesis and ECM production in vitro [28]. In vivo, an RCT assessed the potency of nicardipine using 0.9% saline injections as a control and revealed a significant benefit of nicardipine in pain, erectile function, and plaque size, but not in penile curvature [86].

Hyaluronic Acid (HA)

Hyaluronic acid has been known to reduce scar formation and disrupt inflammatory and oxidative stress processes. In this context, its probable positive effect on the inflammatory and pre-fibrotic states of PD was investigated in a single-arm prospective study including 65 patients receiving 10 weekly injections with HA. This study demonstrated a statistically significant improvement in plaque size, curvature, erectile function, and pain and constituted the basis for further, more reliable research [26]. In fact, HA was compared with a commonly offered regimen in PD, meaning IVI. The outcomes were contradictory, with a non-randomized prospective study concluding that HA is superior to IVI as regards plaque size, curvature, pain, erectile function, and patient satisfaction, while an RCT detected no significant intergroup differences in these measures except for curvature and patient satisfaction. None of these two studies reported any injection-site ecchymosis or hematomas [87,88]. It is highly important to underline that none of the aforementioned studies followed the same injection protocol, with the duration varying from eight to 12 weeks. As soon as there was controversy about the true effect of HA in acute PD, the simultaneous administration of oral and intralesional HA was examined against intralesional HA monotherapy and proved to be more effective with respect to plaque size, penile deviation, pain, erectile function, and patients’ impression of improvement [89].

Corticosteroids

Taking into account that during the early stages of PD inflammatory processes are at the forefront, a direct intraplaque administration of a potent and easily accessible anti-inflammatory agent, such as methylprednisolone, hypothetically would be beneficial for this condition. Actually, this hypothesis was not completely verified in the setting of a prospective single-arm study where eight-weekly intralesional injections of methylprednisolone failed to accomplish a statistically significant decrease in penile curvature and IIEF-5 score, whereas managed to improve plaque size and all PD Questionnaire aspects [27].

Platelet-Rich Plasma (PRP)

Platelet-rich plasma, which is produced by a fraction of autologous blood enriched with platelets, appears to have a regulatory role in inflammation and extracellular matrix remodeling. Its efficacy on PD was investigated in a small pilot study including 17 patients with PD in the early stages who underwent a series of three injections every 15 days. The study manifested that PRP injections are both safe and efficient, leading not only to a significant penile curvature decrease but also to an improvement in physical and psychological symptoms as well as discomfort [32]. A better context for efficacy assessment was provided by a prospective study that compared PRP injections with placebo injections of 0.9% saline. It was reported that the intervention group experienced a statistically significant improvement in penile deviation, plaque size, plaque softening, pain, and IIEF-5 score. Last but not least, both studies did not observe any significant side effects [90].

Extracorporeal Shock Wave Therapy (ESWT)

Extracorporeal shock wave therapy was first applied in a population consisting of 26 patients with a PD duration of less than three months. Despite the small population, ESWT seemed to have a great analgesic effect and improve erectile function even after only one session [30]. In a more recent randomized controlled double-blind trial, where the therapeutic plan included four weekly sessions of ESWT, it was manifested that ESWT can be an efficient treatment modality in terms of erectile pain, erectile function, and overall quality of life. Moreover, even if no statistical significance was reached, ESWT achieved stability in penile curvature and plaque size in contrast with the placebo group, which experienced disease progression [91]. The results emerging from a recent large retrospective study point in the same direction, demonstrating that ESWT is significantly associated with pain alleviation and erectile function improvement. However, ESWT seemed to have no effect on the natural course of the disease with respect to penile curvature, which worsened at first and then stabilized [92]. In fact, the same efficacy profile of ESWT in active-phase PD arose from two studies that designate ESWT only as a potent analgesic modality [93, 94]. It is important to highlight that no significant or long-term adverse effects were observed except for mild local discomfort.

Electromotive Administration

It has been hypothesized that electromotive administration can provide a more efficient drug delivery to the TA, along with less discomfort due to multiple injections. This hypothesis was investigated by a randomized study with 60 patients during the acute phase of PD comparing the administration of verapamil and dexamethasone either electromotively or intralesionally without including side effects in its endpoints. This study was only able to provide indications and no reliable conclusions about the superiority of electromotive administration in improving penile curvature, plaque size, erectile function, and pain [95]. Additionally, another larger RCT set the electromotive administration of either verapamil and dexamethasone or lidocaine side by side. The lidocaine arm exhibited equal results with the intervention arm regarding pain reduction, while intergroup differences in plaque size and penile deviation were statistically significant in favor of the verapamil and dexamethasone combination. Besides a transient erythema at the sites of the electrodes, no other complications were reported [96].

Penile Traction Therapy (PTT)

The sole study investigating the effect of PTT in patients with acute phase PD was a non-randomized prospective controlled trial including 95 patients. More specifically, 55 patients who followed a therapeutic scheme, which demanded the use of a traction device at least six hours daily for six months, were compared with 41 patients who did not agree to accept any therapeutic option during the acute phase. This study manifested that PTT achieved a mean decrease of 20o (p< 0.05) from baseline curvature, an increase in stretched penile length and flaccid girth (p = 0.03), and a decrease in mean VAS pain score from 5.5 to 2.5 at six months of treatment (p<0.05). Also, PTT decreased the percentage of patients who were not able to penetrate (from 61.8% to 20% at six months, p< 0.03). On the other hand, in the no-intervention group, penile curvature, pain during erection, and the percentage of patients unable to penetrate all worsened to a statistically significant degree. Regarding the safety of PTT, no major complications were reported except for discomfort and erythema of the balanoprepucial sulcus [31].

Combination

The fact that monotherapies are not capable of improving all aspects of the PD clinicopathological spectrum has motivated many teams to seek out more efficient treatment strategies in combinations of regimens. The combination of oral agents and intralesional therapy has been well scrutinized, leading to contradicting results. Interferon-2b injections alongside vitamin E administration proved no statistically significant improvement in subjective parameters while merging verapamil injections with oral tadalafil resulted in an erectile function enhancement and plaque size shrinking despite no effect on penile curvature [29,97].

In addition, it was hypothesized that tadalafil can have synergistic effects not only with verapamil but also with ESWT. This hypothesis was tested in an RCT that performed a head-to-head comparison between tadalafil accompanied with ESWT and ESWT monotherapy. None of these two therapeutic strategies achieved a statistically significant improvement in pain and curvature degree after 24 weeks, and no intergroup superiority regarding pain and penile curvature was observed. However, it was manifested that adding tadalafil to ESWT improved in a statistically significant degree the 24-month IIEF-5 and Quality of Life (QoL) scores [98]. Similar conclusions arise from a small randomized controlled study where 20 patients were randomly assigned to either low-dose daily tadalafil for three months or to four low-energy ESWT sessions. Both of these treatment modalities improved erectile function during the acute stage of the disease, but penile curvature and plaque size were not significantly altered in both groups [99].

Given that PTT has offered some encouraging results even as monotherapy in acute PD, it was also inspected as part of a multi-treatment strategy. First of all, a large retrospective study with 170 patients revealed that intralesional verapamil injections, PTT, and antioxidants combined achieved improvements in mean penile curvature and stretched penile length but without any statistical significance, but they were adequate to significantly increase the mean IIEF-5 score. However, it is important to underline that due to a lack of motivation and skepticism about results, many patients refused to complete the injection and traction therapies [100]. On the other hand, an RCT that compared an arm receiving PTT and antioxidants with a control arm undergoing only verapamil injections concluded that combination treatment managed to significantly reduce both pain and penile curvature, in contrast with intralesional verapamil therapy, which failed to offer any benefit. Sadly, none of the two arms showed any improvement regarding plaque size, penile length, or IIEF-5 scores [101].

Current limitations and future perspectives

The differentiation between acute and stable phases of PD is based on clinical criteria. However, among the guideline panels, there is no well-accepted time point established as a cut-off for acute phase PD, while regarding the definition of stable phase PD, there is both agreement and discrepancy [102]. Moreover, the lack of consensus with respect to definitions of the disease phases is profound in PD intervention studies found in literature, where heterogeneous criteria, including total symptom duration, presence of pain, or duration of stable symptoms, are commonly utilized [103]. This comes to an agreement with our own experience during the conduct of this review, where no consistent definition was used across the studies, leading to a significant degradation of their internal validity and quality of evidence. Based on these discrepancies in definitions, additional tools might assist clinicians in distinguishing the two phases of the disease, such as NLR and PLR or ultrasound imaging [6,53].

One treatment modality that seems to have promising results is PTT, which can be effective in penile curvature, pain, and erectile function improvement both as monotherapy or combined with oral and intralesional therapies [31,100,101]. Although there is no standardized protocol for traction device usage, given that they should be used for at least three hours daily, in the particular studies the utilization patterns were adequate [104]. Moreover, traction therapy demands the tolerance of prolonged forces on the penis daily for six months in most studies. The long therapy duration has been proven to be a factor in poor compliance and can alter the subjective opinion of the patient about the therapy’s effectiveness [105]. Furthermore, it is not only the compliance rates an issue regarding reliable study design but also the short follow-up periods. For example, IIEF-5 scores cannot be calculated three months after treatment considering that IIEF-5 evaluates erectile function during the last six months. Last but not least, the prolongation of follow-up will provide precious results regarding the duration of response and long-term adverse effects.

According to European Association of Urology (EAU) and American Urological Association (AUA) guidelines, it is suggested, with a low level of evidence, that only intralesional CCh or interferon and PTT can be offered as treatment options to the patient, while oral regimens are not proposed as treatment options due to a lack of either evidence or efficacy, with the sole exception being PDE5is. In addition, ESWT can be a useful tool in order to improve penile pain [67,87,89,106]. However, due to the recent withdrawal of CCh from many countries, an increase in interest in combination therapies has emerged [107]. The lack of high-quality RCTs, where only recommended regimens are combined, stands in the way of reaching a consensus on reliable combination strategies [18]. Additionally, the absence of high-quality evidence does not only refer to combination treatments but also to oral therapies. For example, given that the only study investigating the efficacy of CoQ was published by an author with two retracted RCTs regarding other orally administered compounds, there are some concerns with respect to the integrity and reliability of the study [108,109].

The pathophysiology as well as the molecular paths being involved in the pathogenesis of the disease are not completely elucidated. This can be partially explained by the fact that many relevant translational research studies have included animal models and cultured PD plaques, which has significant limitations, and additionally by the difficulty to superimpose knowledge about other fibrotic diseases on PD due to heterogeneity of fibroblasts and ECM in different tissues [110]. In the context of broadening our knowledge about molecular cascades responsible for PD development, the yes-activated protein (YAP) was investigated. The YAP pathway is significantly activated in PD fibroblasts and can be inhibited by Verteporfin, a molecular inhibitor of the hippo-YAP pathway, which can constitute a promising future therapy [111]. Last, but not least, based upon the innovative insights about PD pathophysiology, Scutellaria baicalensis extract, a flavonoid that downregulates monocyte chemoattractant protein 1 (MCP-1) administered to active phase PD patients by oral route for six months, posed a significant impact in pain decrease, plaque volume reduction, and need for surgical repair of the curvature compared with the untreated control group [112].

Conclusions

Acute phase PD is a challenging entity with respect to both diagnosis and management. The treatment strategy has shifted from traditional oral therapies to new combination modalities. The majority of these multimodal treatments include CCh, PPT, and PDE5Is. Large, well-designed RCTs are necessary to establish a standard of care in the treatment of this condition. Optimistically, as more light is shed on the pathophysiology of the disease, new agents might emerge and solve the acute phase PD treatment riddle.

Disclosures

Author Contributions

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Konstantinos Douroumis, Konstantinos Kotrotsios, Evangelos Fragkiadis, Dionysios Mitropoulos, Ioannis Adamakis

Acquisition, analysis, or interpretation of data:  Konstantinos Douroumis, Konstantinos Kotrotsios, Panagiotis Katsikatsos, Napoleon Moulavasilis

Drafting of the manuscript:  Konstantinos Douroumis, Konstantinos Kotrotsios, Panagiotis Katsikatsos, Napoleon Moulavasilis

Critical review of the manuscript for important intellectual content:  Evangelos Fragkiadis, Dionysios Mitropoulos, Ioannis Adamakis

Supervision:  Dionysios Mitropoulos, Ioannis Adamakis
==== Refs
References

1 Peyronie's disease development and management in diabetic men Andrology Gianazza S Belladelli F Leni R 372 378 11 2023 35771713
2 The prevalence of Peyronie's disease: results of a large survey BJU Int Schwarzer U Sommer F Klotz T Braun M Reifenrath B Engelmann U 727 730 88 2001 11890244
3 A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States Adv Urol Dibenedetti DB Nguyen D Zografos L Ziemiecki R Zhou X 282503 2011 2011 22110491
4 The prevalence of Peyronie's disease in the United States: a population-based study PLoS One Stuntz M Perlaky A des Vignes F Kyriakides T Glass D 0 11 2016
5 Peyronie’s disease: a review of etiology, diagnosis, and management Curr Sex Health Rep Bilgutay AN Pastuszak AW 117 131 7 2015 26279643
6 US imaging in Peyronie's disease J Clin Imaging Sci Kalokairinou K Konstantinidis C Domazou M Kalogeropoulos T Kosmidis P Gekas A 63 2 2012 23230545
7 An analysis of the natural history of Peyronie's disease J Urol Mulhall JP Schiff J Guhring P 2115 2118 175 2006 16697815
8 Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up Transl Androl Urol Al-Thakafi S Al-Hathal N 280 289 5 2016 27298774
9 The chronology of depression and distress in men with Peyronie's disease J Sex Med Nelson CJ Diblasio C Kendirci M Hellstrom W Guhring P Mulhall JP 1985 1990 5 2008 18554257
10 Psychological impact of Peyronie's disease: a review J Sex Med Nelson CJ Mulhall JP 653 660 10 2013 23153101
11 Guidelines EAU Annual Congress Milan. Accessed: July 22, 2024 7 2024 2023 https://uroweb.org/guidelines
12 L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures Nitric Oxide Valente EG Vernet D Ferrini MG Qian A Rajfer J Gonzalez-Cadavid NF 229 244 9 2003 14996430
13 The use of tocopherols in the treatment of Peyronie's disease Ann New York Acad Sci Scardino PL Scott WW 390 393 52 1949
14 Treatment of Peyronie's disease with procarbazine Br J Urol Oosterlinck W Renders G 219 220 47 1975 1148623
15 Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study Res Rep Urol Paulis G Barletta D Turchi P Vitarelli A Dachille G Fabiani A Gennaro R 1 10 8 2016 26770906
16 Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study Int J Impot Res Safarinejad MR 298 309 22 2010 20720560
17 Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report BJU Int Biagiotti G Cavallini G 63 67 88 2001 11446848
18 Assessment of conservative combination therapies for active and stable Peyronie's disease: a systematic review and meta-analysis Eur Urol Focus Pyrgidis N Yafi FA Sokolakis I 1520 1530 8 2022 34924336
19 Treatment of Peyronie’s disease with potassium para-aminobenzoate (potaba) J Urol Zarafonetis CJD Horrax TM 770 772 81 1959 13655401
20 The treatment of Peyronie's disease with tamoxifen Br J Urol Ralph DJ Brooks MD Bottazzo GF Pryor JP 648 651 70 1992 1486392
21 Disappearance of plaque following treatment with antioxidants in Peyronie's disease patients-a report of 3 cases Clin Pract Paulis G De Giorgio G 1020 1033 12 2022 36547113
22 Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study Inflamm Allergy Drug Targets Paulis G Cavallini G Giorgio GD Quattrocchi S Brancato T Alvaro R 403 409 12 2013 24304332
23 Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease Eur Urol Riedl CR Plas E Vorauer K Vcelar B Wagner A Pflüger H 343 348 40 2001 11684853
24 Efficacy of collagenase Clostridium histolyticum (Xiapex(®)) in patients with the acute phase of Peyronie’s disease Clin Drug Investig Cocci A Di Maida F Russo GI 583 588 40 2020
25 Intralesional verapamil injection for the treatment of Peyronie's disease J Urol Levine LA Merrick PF Lee RC 1522 1524 151 1994 8189561
26 Intralesional injection of hyaluronic acid in patients affected with Peyronie's disease: preliminary results from a prospective, multicenter, pilot study Sex Med Zucchi A Costantini E Cai T 0 8 4 2016
27 Intralesional low-dose methylprednisolone for the treatment of active phase Peyronie's disease: a single-centre, preliminary prospective non-randomised study Int J Clin Pract Ure I Ozen A 0 75 2021
28 Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial J Sex Med Soh J Kawauchi A Kanemitsu N 3743 3749 7 2010 20584114
29 Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study Urology Inal T Tokatli Z Akand M Ozdiler E Yaman O 1038 1042 67 2006 16581113
30 Extra-corporeal lithotripsy in the treatment of Peyronie's disease. Use of a standard lithotriptor (Multiline Siemens) on "young" (less then 6 months old) plaques (Article in French) Prog Urol Lebret T Hervé JM Lugagne PM Barré P Orsini JL Butreau M Botto H 65 1 10 2000 https://pubmed.ncbi.nlm.nih.gov/10785921/ [Last accessed on 2024 July 22] 10785921
31 Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation J Sex Med Martínez-Salamanca JI Egui A Moncada I 506 515 11 2014 24261900
32 Tolerance and efficacy of platelet-rich plasma injections in Peyronie's disease: pilot study Prog Urol Schirmann A Boutin E Faix A Yiou R 856 861 32 2022 35778315
33 Proposal: trauma as the cause of the Peyronie's lesion J Urol Devine CJ Jr Somers KD Jordan SG Schlossberg SM 285 290 157 1997 8976281
34 Peyronie's disease: what's around the bend? Indian J Urol Bilgutay AN Pastuszak AW 6 14 32 2016 26941488
35 Understanding the course of Peyronie's disease Int J Clin Pract Garaffa G Trost LW Serefoglu EC Ralph D Hellstrom WJ 781 788 67 2013 23869679
36 The genetic basis of Peyronie disease: a review Sex Med Rev Herati AS Pastuszak AW 85 94 4 2016 27872008
37 The impact of the extracellular matrix on inflammation Nat Rev Immunol Sorokin L 712 723 10 2010 20865019
38 Extracellular matrix alterations in the Peyronie's disease J Adv Res Watanabe MS Theodoro TR Coelho NL 455 461 8 2017 28721300
39 Reciprocal regulation of TGF-β and reactive oxygen species: a perverse cycle for fibrosis Redox Biol Liu RM Desai LP 565 577 6 2015 26496488
40 Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque Urology Davila HH Magee TR Zuniga FI Rajfer J Gonzalez-Cadavid NF 645 648 65 2005 15833499
41 Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts J Urol Del Carlo M Cole AA Levine LA 2447 2455 179 2008 18433786
42 CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis Fibrogenesis Tissue Repair Lipson KE Wong C Teng Y Spong S 0 5 2012
43 Drugs of the future for Peyronie's disease Med Hypotheses Gur S Kadowitz PJ Hellstrom WJ 305 311 78 2012 22154542
44 Histologic study of the tunica albuginea of the penis and mode of cavernosus muscles' insertion in it Arch Androl Shafik A El-Sharkawy A Khamis A Zaghloul S Abdel Gawad M Elwy D 1 8 52 2006 16338862
45 Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease J Urol Hauck EW Hauptmann A Schmelz HU Bein G Weidner W Hackstein H 369 372 169 2003 12478192
46 Chromosome abnormalities in Peyronie's disease J Urol Somers KD Winters BA Dawson DM 672 675 137 1987 3560320
47 WNT2 locus is involved in genetic susceptibility of Peyronie's disease J Sex Med Dolmans GH Werker PM de Jong IJ Nijman RJ Wijmenga C Ophoff RA 1430 1434 9 2012 22489561
48 Comparison of apoptotic gene expression profiles between Peyronie's disease plaque and tunica albuginea Adv Clin Exp Med Zorba OU Sirma S Ozgon G Salabas E Ozbek U Kadioglu A 607 614 21 2012 https://pubmed.ncbi.nlm.nih.gov/23356197/ [Last accessed on 2024 July 22] 23356197
49 Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis J Immunol Wynes MW Edelman BL Kostyk AG 527 537 187 2011 21632719
50 Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie's disease BJU Int Kwon KD Choi MJ Park JM 926 936 114 2014 24841412
51 The natural history of Peyronie's disease World J Mens Health Di Maida F Cito G Lambertini L 399 405 39 2021 32648381
52 Deformity stabilization and improvement in men with untreated Peyronie's disease BJU Int Berookhim BM Choi J Alex B Mulhall JP 133 136 113 2014 24053665
53 Role of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in Peyronie's disease: a new diagnostic approach to predict the stage of the disease? Asian J Androl Garcia Rojo E García Gómez B Santos-Pérez de la Blanca R 325 329 23 2021 33353905
54 Surgery for Peyronie's disease Asian J Androl Levine LA Larsen SM 27 34 15 2013 23178395
55 A clinical pathway for the management of Peyronie's disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association BJU Int Chung E Gillman M Tuckey J La Bianca S Love C 12 17 126 Suppl 1 2020 32542884
56 Review of management options for active-phase Peyronie's disease Sex Med Rev Brimley SC Yafi FA Greenberg J Hellstrom WJ Tue Nguyen HM Hatzichristodoulou G 329 337 7 2019 30503796
57 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ Page MJ McKenzie JE Bossuyt PM 0 372 2021
58 Procarbazine (Natulan) in the treatment of Peyronie's disease Br J Urol Morgan RJ Pryor JP 111 113 50 1978 754844
59 Is colchicine effective in Peyronie's disease? A pilot study Urology Akkus E Carrier S Rehman J Breza J Kadioglu A Lue TF 291 295 44 1994 8048212
60 Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome Int J Impot Res Kadioglu A Tefekli A Köksal T Usta M Erol H 169 175 12 2000 11045911
61 Peyronie's disease in men under age 40: characteristics and outcome Int J Impot Res Tefekli A Kandirali E Erol H Alp T Köksal T Kadioğlu A 18 23 13 2001 11313836
62 Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study Int J Impot Res Safarinejad MR 238 243 16 2004 14973528
63 The most commonly altered type of Peyronie's disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side Andrologia Akman T Sanli O Uluocak N Akbulut F Nane I Demir S Kadioglu A 28 33 43 2011 21219379
64 Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA) (author's transl) (Article in German) Urologe A Hasche-Klünder R 224 227 17 1978 https://pubmed.ncbi.nlm.nih.gov/308273/ [Last accessed on 2024 July 22] 308273
65 A multicentre doubleblind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie's disease Prog Reprod Biol Med Shah PJ Green NA Adib RS Pryor JP 61 67 9 1983 https://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1983&pages=61-67&journal=Progr+Reprod+Biol+Med&author=Shah+P.J.R.&author=Green+N.A.&author=Adib+R.S.&author=Hamilton+Stewart+P.A.&author=Smith+P.&author=Coxon+R.&title=A+multicentre+double-blind+controlled+clinical+trial+of+potassium+para-amino-benzoate+%28POTABA%C2%AE%29+in+Peyronie%27s+disease [Last accessed on 2024 July 22]
66 Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective? Tech Urol Carson CC 135 139 3 1997 https://pubmed.ncbi.nlm.nih.gov/9422444/ [Last accessed on 2024 July 22] 9422444
67 Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study Eur Urol Weidner W Hauck EW Schnitker J 530 535 47 2005 15774254
68 The efficacy of medical treatment of Peyronie's disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitor World J Mens Health Park TY Jeong HG Park JJ 40 46 34 2016 27169128
69 Controlled clinical trial of vitamin E in Peyronie's disease Prog Reprod Biol Med Pryor JP Farell CR 41 45 9 1983 https://scholar.google.com/scholar_lookup?journal=Prog+Reprod+Biol&title=Controlled+clinical+trial+of+vitamin+E+in+Peyronie%27s+disease.&author=JP+Pryor&author=CF+Farrell&volume=9&publication_year=1983&pages=41-5& [Last accessed on 2024 July 22]
70 Outcome analysis for conservative management of Peyronie's disease Int J Urol Hashimoto K Hisasue S Kato R Kobayashi K Shimizu T Tsukamoto T 244 247 13 2006 16643617
71 Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study J Urol Safarinejad MR Hosseini SY Kolahi AA 1398 1403 178 2007 17706714
72 Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases Andrology Paulis G Brancato T D'Ascenzo R De Giorgio G Nupieri P Orsolini G Alvaro R 120 128 1 2013 23258640
73 Tamoxifen versus placebo in the treatment of Peyronie's disease J Urol Teloken C Rhoden EL Grazziotin TM Ros CT Sogari PR Souto CA 2003 2005 162 1999 10569556
74 A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals J Sex Med Cellek S Megson M Ilg MM Ralph DJ 1057 1059 20 2023 37524687
75 The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes J Sex Med Chung E Deyoung L Brock GB 1472 1477 8 2011 21324095
76 Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction Ir J Med Sci Ozturk U Yesil S Goktug HN 449 453 183 2014 24190613
77 Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis Int J Impot Res Spirito L Manfredi C La Rocca R 129 134 36 2024 36513814
78 Effects of long term sildenaﬁl on the acute phase of Peyronie's disease in a combination treatment Arch Ital Urol Androl Topcuoglu M Çakan M 319 322 94 2022 36165478
79 Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study Eur Urol Riedl CR Sternig P Gallé G 656 661 48 2005 15982798
80 Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study Int J Impot Res Twidwell J Levine L 41 45 28 2016 26700214
81 Safety and efficacy of Collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie's disease J Sex Med Nguyen HM Anaissie J DeLay KJ Yafi FA Sikka SC Hellstrom WJ 1220 1225 14 2017 28874331
82 Safety and efficacy of Collagenase Clostridium histolyticum in the treatment of acute phase Peyronie's disease: a multi-institutional analysis Urology Nguyen HM Yousif A Chung A 147 151 145 2020 32777367
83 Intralesional collagenase Clostridium histolyticum for acute phase Peyronie's disease: a single-center, retrospective cohort study Transl Androl Urol Hu MY Sigalos JT Walker DT 1074 1082 11 2022 36092841
84 Intralesional verapamil prevents the progression of Peyronie's disease Urology Bennett NE Guhring P Mulhall JP 1181 1184 69 2007 17572211
85 Analysis of intralesional verapamil (ILV) therapy for Peyronie's disease Journal Sex Med Cimmino C Bennett N 17 8 2011 https://academic.oup.com/jsm/article-abstract/8/Supplement_1/4/6986624?redirectedFrom=fulltext [Last accessed on 2024 July 22]
86 Effects of calcium channel blockers on formalin-induced nociception and inflammation in rats Pharmacology Gürdal H Sara Y Tulunay FC 290 296 44 1992 1620724
87 Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study Andrology Favilla V Russo GI Zucchi A 771 775 5 2017 28718527
88 Comparison of intralesional hyaluronic acid vs. verapamil for the treatment of acute phase Peyronie's disease: a prospective, open-label non-randomized clinical study World J Mens Health Cocci A Di Maida F Cito G 352 357 39 2021 32009312
89 Oral administration and intralesional injection of hyaluronic acid versus intralesional injection alone in Peyronie's disease: results from a phase III study World J Mens Health Cai T Tiscione D Favilla V 526 532 39 2021 33151042
90 Platelet-rich plasma therapy of Peyronie's disease Journal Sex Med Notsek M Boiko M 0 16 2019
91 A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease Eur Urol Palmieri A Imbimbo C Longo N 363 369 56 2009 19473751
92 Long-term outcomes of extracorporeal shock wave therapy for acute Peyronie's disease: a 10-year retrospective analysis Int J Impot Res Spirito L Manfredi C La Rocca R 135 139 36 2024 36788352
93 Peyronie's disease and low intensity shock wave therapy: clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men Korean J Urol Chung E 775 780 56 2015 26568796
94 Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience Asian J Androl Abdessater M Akakpo W Kanbar A 45 49 24 2022 34045390
95 Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease Andrology Mehrsai AR Namdari F Salavati A Dehghani S Allameh F Pourmand G 129 132 1 2013 23258641
96 A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease J Urol Di Stasi SM Giannantoni A Stephen RL Capelli G Giurioli A Jannini EA Vespasiani G 1605 1608 171 2004 15017231
97 Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie's disease Urol Ann Dell'Atti L 345 349 7 2015 26229323
98 Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial Int J Androl Palmieri A Imbimbo C Creta M Verze P Fusco F Mirone V 190 195 35 2012 22085227
99 Effect of low-dose PDE5i and low-energy shock wave on acute phase of Peyronie's disease J Sex Med Lu M 118 119 17 2020
100 Ten-year experience with multimodal treatment for acute phase Peyronie's disease: a real life clinical report Actas Urol Esp (Engl Ed) Gallo L Sarnacchiaro P 182 189 43 2019 30704797
101 Combination of Andropenis® penile extender and oral therapy (Peironimev ®) versus intralesional verpamil for penile curvature due to Peyronie's disease: preliminary results of a randomized phase II trial Urology Gontero P Di Marco M Giubilei G 0 78 2011
102 Comparing and contrasting Peyronie's disease guidelines: points of consensus and deviation J Sex Med Manka MG White LA Yafi FA Mulhall JP Levine LA Ziegelmann MJ 363 375 18 2021 33423972
103 A consistent lack of consistency in defining the acute and chronic phases of Peyronie's disease: a review of the contemporary literature Sex Med Rev Piraino J Chaudhary H Ames K 698 713 10 2022
104 Penile traction therapy and Peyronie's disease: a state of art review of the current literature Ther Adv Urol Chung E Brock G 59 65 5 2013 23372611
105 Outcomes of RestoreX penile traction therapy in men with Peyronie's disease: results from open label and follow-up phases J Sex Med Joseph J Ziegelmann MJ Alom M Savage J Köhler TS Trost L 2462 2471 17 2020 33223425
106 Peyronie's disease: AUA guideline J Urol Nehra A Alterowitz R Culkin DJ 745 753 194 2015 26066402
107 The end of an era: withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European market Eur Urol Cocci A Russo GI Salamanca JI Ralph D Palmieri A Mondaini N 660 661 77 2020 31810821
108 RETRACTED: Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: a prospective, randomized, double-blind placebo-controlled study J Sex Med Safarinejad MR 1743 1754 6 2009 19453924
109 A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease BJU Int Safarinejad MR Asgari MA Hosseini SY Dadkhah F 240 248 106 2010 19863517
110 New insights into the pathogenesis of Peyronie's disease: a narrative review Chronic Dis Transl Med Krakhotkin DV Chernylovskyi VA Mottrie A Greco F Bugaev RA 165 181 6 2020 32885153
111 Verteporfin as a medical treatment in Peyronie's disease Sex Med Mohede DC de Jong IJ Bank RA van Driel MF 302 308 6 2018 30274909
112 Treatments of Peyronie's disease with Scutellaria baicalensis and surgery according to the disease course: a single-center retrospective study of 261 patients Ann Palliat Med Li WJ Bao J Zheng DC Guo J Xie MK Chen HY Wang Z 2979 2989 10 2021 33615818
